Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Amgen metabolic, cardiovascular, renal news

AMGN subsidiary Ilypsa Inc. spun out Relypsa Inc. to discover and develop non-absorbed polymeric therapeutics

Read the full 159 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE